Stock listing

Dusseldorf:9IP1 Rocket Pharmaceuticals, Inc. Aktie

German listing (Dusseldorf) of Rocket Pharmaceuticals, Inc. · home listing NASDAQ:RCKT

Follow Rocket Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:RCKT

$1.95 USD -0.16 (-7.6%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:RCKT

Past year -31.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.94 – $2.18 USDNov 20, 2026
Volume
2.90M sharesNov 20, 2026
Market cap
$214.1M USDAt the close on Nov 20, 2026 · price × 109.8M shares outstanding
52-week range
$1.94 – $5.45 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$5.16M USDMedian day 1.79M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Rocket Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:RCKT · Home$1.95 USD-0.16 (-7.6%)2,898,098$2.07$2.175$1.94$2.11Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RCKT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.95-0.16-7.6%$2.07$2.175$1.942,898,098
$2.110.000.0%$2.09$2.215$2.062,491,533
$2.11-0.05-2.3%$2.16$2.195$2.031,785,037
$2.16-0.14-6.1%$2.28$2.35$2.151,919,496
$2.30-0.09-3.8%$2.30$2.365$2.1911,783,377
$2.39-0.09-3.6%$2.45$2.46$2.35954,292
$2.48+0.03+1.2%$2.44$2.545$2.40962,708
$2.45-0.08-3.2%$2.50$2.58$2.4051,224,137
$2.53+0.145+6.1%$2.40$2.57$2.311,759,082
$2.385-0.05-2.1%$2.41$2.51$2.361,425,517
$2.435-0.175-6.7%$2.60$2.60$2.302,180,843
$2.61+0.10+4.0%$2.60$2.66$2.4751,648,666
$2.51+0.04+1.6%$2.49$2.635$2.421,286,821
$2.47+0.03+1.2%$2.44$2.495$2.391,818,871
$2.44-0.10-3.9%$2.50$2.57$2.371,535,033
$2.54-0.04-1.6%$2.58$2.67$2.501,829,544
$2.58+0.13+5.3%$2.42$2.605$2.3721,418,501
$2.45+0.17+7.5%$2.29$2.52$2.2532,054,567
$2.28-0.01-0.4%$2.29$2.291$2.221,514,755
$2.29-0.02-0.9%$2.27$2.29$2.171,601,100
$2.31+0.11+5.0%$2.20$2.34$2.182,163,500
$2.20-0.14-6.0%$2.34$2.385$2.172,022,800
$2.34+0.10+4.5%$2.24$2.37$2.201,889,400
$2.24+0.06+2.8%$2.18$2.29$2.1651,850,300
$2.18-0.18-7.6%$2.36$2.36$2.171,966,800
$2.36+0.15+6.8%$2.22$2.395$2.2071,878,200
$2.21-0.09-3.9%$2.26$2.295$2.182,009,400
$2.30-0.18-7.3%$2.47$2.55$2.263,891,300
$2.48-0.08-3.1%$2.54$2.595$2.462,302,700
$2.56-0.07-2.7%$2.59$2.688$2.543,369,700
$2.63+0.095+3.7%$2.78$2.78$2.523,455,900
$2.535+0.055+2.2%$2.45$2.64$2.422,808,500
$2.48-0.13-5.0%$2.61$2.62$2.461,788,300
$2.61+0.05+2.0%$2.59$2.63$2.501,658,500
$2.56-0.03-1.2%$2.64$2.66$2.531,818,400
$2.59-0.04-1.5%$2.62$2.745$2.582,091,900
$2.63+0.04+1.5%$2.62$2.73$2.552,526,800
$2.59-0.02-0.8%$2.63$2.646$2.561,153,100
$2.61+0.015+0.6%$2.57$2.62$2.512,074,000
$2.595-0.095-3.5%$2.80$2.80$2.572,626,700
$2.69-0.33-10.9%$3.00$3.025$2.664,382,300
$3.02-0.33-9.9%$3.33$3.335$2.9532,777,400
$3.35+0.08+2.4%$3.29$3.41$3.281,072,800
$3.27-0.10-3.0%$3.40$3.405$3.2651,355,300
$3.37-0.13-3.7%$3.47$3.56$3.351,597,900
$3.50+0.02+0.6%$3.59$3.755$3.481,858,400
$3.48+0.07+2.1%$3.565$3.57$3.402,644,200
$3.41-0.02-0.6%$3.65$3.685$3.213,660,100
$3.43+0.08+2.4%$3.29$3.475$3.291,293,400
$3.35-0.13-3.7%$3.52$3.52$3.251,655,900
$3.48-0.15-4.1%$3.62$3.63$3.441,185,400
$3.63-0.08-2.2%$3.67$3.755$3.62871,400
$3.71-0.15-3.9%$3.78$3.782$3.68754,700
$3.86+0.07+1.8%$3.75$3.88$3.73888,500
$3.79-0.07-1.8%$3.90$3.915$3.691,070,300
$3.86+0.13+3.5%$3.71$3.955$3.711,162,500
$3.73+0.01+0.3%$3.72$3.805$3.674948,700
$3.72-0.14-3.6%$3.77$3.80$3.6361,601,600
$3.86+0.24+6.6%$3.61$3.99$3.533,454,300
$3.62-0.04-1.1%$3.63$3.76$3.591,258,500
$3.66-0.12-3.2%$3.73$3.73$3.581,120,200
$3.78+0.25+7.1%$3.54$3.81$3.5362,201,500
$3.53+0.02+0.6%$3.53$3.55$3.375913,300
$3.51+0.03+0.9%$3.52$3.605$3.48939,800
$3.48-0.17-4.7%$3.60$3.659$3.431,111,200

Splits

1 split · NASDAQ:RCKT · every price before a split is adjusted for it

DayRatioWhat
1-for-4Consolidation
Ticker
Dusseldorf:9IP1
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Dusseldorf
Currency
EUR

What changed lately

Latest news

All Rocket Pharmaceuticals, Inc. news

Rocket Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
15 in the last 12 months · 183 in all · newest Nov 12, 2026 · oldest 2019
Calls
1 call with a replay · 1 with a transcript · latest Aug 9, 2021
Decks
44 decks · latest November 2026

Where Rocket Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:RCKT · Home listingNASDAQUnited StatesUSD
LS Exchange:A2JA9QLS ExchangeGermanyEUR
gettex:9IP1gettexGermanyEUR
Lang & Schwarz:A2JA9QLang & SchwarzGermanyEUR
BOATS:RCKTBOATSUnited StatesUSD
Tradegate:9IP1TradegateGermanyEUR
Dusseldorf:9IP1 · This pageDusseldorfGermanyEUR
Frankfurt:9IP1FrankfurtGermanyEUR
Hamburg:9IP1HamburgGermanyEUR
Munich:9IP1MunichGermanyEUR
Stuttgart:9IP1StuttgartGermanyEUR

Valuation

Price/book 0.7× against a median of 1.6×: 2nd lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$25.02M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.7×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.1×
Beta vs S&P 500
1.72

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Rocket Pharmaceuticals, Inc. · NASDAQ:RCKTUS$214.1M−US$25.02Mn/an/an/a0.7×n/a0.1×1.72
Allogene Therapeutics, Inc. · NASDAQ:ALLOUS$217.5M−US$7.44Mn/a−1.6×n/a0.6×n/a0.2×1.93
ProKidney Corp. · NASDAQ:PROKUS$217.3MUS$77.56Mn/a100×n/an/an/an/a1.61
Pyxis Oncology, Inc. · NASDAQ:PYXSUS$216.5MUS$160.9Mn/an/an/a5.2×n/a0.0×0.89
Oryzon Genomics SA · BME:ORYUS$216.4MUS$206.7Mn/an/an/a1.6×n/a0.1×n/a
Transgene SA · EURONEXT:TNGUS$212.2MUS$112.7Mn/a750×n/a1.8×n/a0.0×n/a
Arcturus Therapeutics Holdings Inc. · NASDAQ:ARCTUS$211.8MUS$45.18Mn/a1.5×n/a1.3×−285.9%0.1×2.01
Century Therapeutics, Inc. · NASDAQ:IPSCUS$211.6MUS$131.9Mn/an/an/a1.0×n/a0.2×2.35
Orum Therapeutics, Inc. · KRX:475830US$211.2MUS$24.07M15.4×n/an/a1.5×n/a0.0×n/a
GemVax & KAEL Co Ltd · KRX:082270US$211.0MUS$206.2Mn/a3.3×21.2×3.8×−14.4%0.4×n/a
AnnJi Pharmaceutical Co., Ltd. · TPEX:7754US$209.9MUS$195.9Mn/a855×n/a16.5×n/a0.0×n/a
Median of the othersUS$212.0MUS$122.3M15.4×51.7×21.2×1.6×−150.1%0.1×1.93

Forecasts

6 strong buy · 1 buy · 6 hold · 1 sell · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
8.58 USD · Analysts' mean
EPS, year to Dec 2026
-0.11 · 4 analysts
Revenue, year to Dec 2026
935.2K · 11 analysts

Team and board

Officers

OfficerRole
Gaurav ShahChief Executive Officer

Board

DirectorRole
Peter FongChairman of the Board
Carsten BoessIndependent Director
David SouthwellDirector
Fady MalikIndependent Director
Gaurav ShahChief Executive Officer
Mikael DolstenDirector
Roderick WongDirector

Events

Calls

CallWhenStatus
Rocket Pharmaceuticals (NASDAQ:RCKT) Q2 2021 Earnings CallMon, Aug 09, 2021 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close−3.8%
Q2 2026Aug 10, 2026 · After close−3.9%
Q1 2026May 7, 2026 · After close−1.1%
Q4 2025Feb 26, 2026+15.7%
Q3 2025Nov 6, 2025 · After close−1.9%
Q2 2025Aug 7, 2025−5.3%
Q1 2025May 8, 2025 · After close−0.7%
Q4 2024Feb 24, 2025 · Before open−4.0%
Q3 2024Nov 7, 2024 · After close+1.2%
Q2 2024Aug 5, 2024 · After close+0.8%
All 20 quarters
QuarterResultsShare move
Q1 2024May 6, 2024 · After close+0.7%
Q4 2023Feb 25, 2024 · After close+1.7%
Q3 2023Nov 7, 2023 · After close−4.4%
Q2 2023Aug 9, 2023 · After close−1.1%
Q1 2023May 4, 2023 · After close+12.4%
Q4 2022Feb 28, 2023 · After close+5.4%
Q3 2022Nov 3, 2022 · After close−4.3%
Q2 2022Aug 8, 2022 · After close+2.5%
Q1 2022May 5, 2022 · After close−5.5%
Q4 2021Feb 24, 2022 · Before open+4.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck36 slidesNovember 2026
Corporate Update (October 2026)Corporate update23 slidesOct 6, 2026
Investor Presentation (August 2026)Investor deck34 slidesAugust 2026
Technical Presentation (May 2025)Technical19 slidesMay 15, 2025
Technical Presentation (November 2024)Technical15 slidesNov 18, 2024
Corporate Update (September 2023)Corporate update25 slidesSep 12, 2023
41st Annual J.P. Morgan Healthcare Conference (January 2023)Conference45 slidesJan 9, 2023
Investor Presentation (December 2022)Investor deck60 slidesDec 12, 2022
64th Annual Meeting of the American Society of Hematology (ASH) 2022Conference16 slidesDecember 2022
64th Annual Meeting of the American Society of Hematology (ASH) 2022Conference15 slidesDecember 2022
All 44 decks
DeckKindSlidesDate
Technical Presentation (December 2022)Technical15 slidesDecember 2022
Investor Presentation (November 2022)Investor deck58 slidesNovember 2022
European Society of Gene & Cell Therapy Annual Meeting 2022Conference22 slidesOct 12, 2022
Technical Presentation (October 2022)Technical20 slidesOct 3, 2022
Investor Presentation (September 2022)Investor deck59 slidesSep 30, 2022
Investor Presentation (September 2022)Investor deck49 slidesSep 9, 2022
Investor Presentation (September 2022)Investor deck49 slidesSeptember 2022
Investor Presentation (September 2022)Investor deck47 slidesSeptember 2022
Investor Presentation (May 2022)Investor deck50 slidesMay 20, 2022
American Society of Gene & Cell Therapy 25th Annual Meeting 2022Conference22 slidesMay 19, 2022
American Society of Gene and Cell Therapy 25th Annual Meeting (May 2022)Conference14 slidesMay 16, 2022
American Society of Gene and Cell Therapy (ASGCT) 2022Conference15 slidesMay 16, 2022
American Society of Gene and Cell Therapy (ASGCT) 2022Conference14 slidesMay 16, 2022
40th Annual J.P. Morgan Healthcare Conference (January 2022)Conference41 slidesJan 10, 2022
Investor Day (December 2021)Investor day19 slidesDec 14, 2021
Investor Presentation (December 2021)Investor deck84 slidesDecember 2021
Investor Presentation (November 2021)Investor deck85 slidesNovember 2021
Investor Presentation (October 2021)Investor deck73 slidesOctober 2021
Investor Presentation (August 2021)Investor deck73 slidesAugust 2021
Investor Presentation (May 2021)Investor deck73 slidesMay 2021
Investor Presentation (May 2021)Investor deck80 slidesMay 2021
Investor Presentation (March 2021)Investor deck76 slidesMarch 2021
Investor Presentation (January 2021)Investor deck78 slidesJanuary 2021
Investor Day (December 2020)Investor day41 slidesDec 7, 2020
Investor Presentation (December 2020)Investor deck76 slidesDecember 2020
19th Biennial Meeting of the European Society for Immunodeficiencies (ESID) 2020Conference15 slidesSep 24, 2020
ASH Breakout Session 2019Conference29 slidesDec 8, 2019
Technical Presentation (April 2019)Technical17 slidesApril 2019
ASGCT 2019Conference16 slides2019
Investor Presentation (November 2018)Investor deck41 slidesNov 26, 2018
Investor Presentation (September 2018)Investor deck34 slidesSeptember 2018
American Society of Gene & Cell Therapy (ASGCT) 2018Conference34 slidesMay 18, 2018
Bloomberg Biotech Innovations Conference 2018Conference30 slidesApr 9, 2018
Investor Presentation (November 2017)Investor deck30 slidesNovember 2017

Open Decks

Financings

RaiseDate
Term loan credit facility with warrants
Tranche closed: US$35M raised · warrants to purchase shares of Rocket's common stock · LifeSci Capital +1
Dealers: LifeSci Capital, PJT
Buyers: Hercules Capital, Inc. (credit facility for up to $150 million; $35 million funded at closing)
Use of proceeds: Support the pivotal Phase 2 study of RP-A501 for Danon disease and advance the broader cardiovascular pipeline
Oct 6, 2026
Public offering of shares of common stock
Made bigger: US$165M · US$12.5 a share · Morgan Stanley +3
Dealers: Morgan Stanley (co-lead), Leerink Partners (co-lead), Cantor (co-lead), LifeSci Capital
Dec 11, 2024

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as INOTEK PHARMACEUTICALS CORP. Priced at US$6.00 a share on Feb 17, 2015.

Price
US$6.00 a share
Shares offered
6,667,000 shares of common stock
Offering size
US$40 million
Underwriters
Cowen and Company, Piper Jaffray, Canaccord Genuity, Nomura · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceAug 29, 2014
Filed publiclyNov 5, 2014
Amended 5 timesNewest Feb 17, 2015
Shares registered with an exchangeFeb 2, 2015
Declared effective by the SECFeb 17, 2015
Final prospectus, with the priceFeb 19, 2015

Open IPO · From the cover of the final prospectus (424B4) filed Feb 19, 2015

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000000
Cost of revenue11.0M9.38M7.10M6.27M5.37M1.15M426.0K330.0K204.0K169.0K
Gross profit-11.0M-9.38M-7.10M-6.27M-5.37M-1.15M-426.0K-330.0K-204.0K-169.0K
Research and development142.0M171.2M186.3M165.6M125.5M105.4M57.9M53.3M14.9M5.99M
Selling, general and administrative86.5M102.0M73.3M58.8M41.8M27.9M17.5M17.9M12.5M9.89M
Operating income-231.7M-273.2M-259.7M-224.3M-167.2M-134.3M-76.2M-71.2M-19.8M-7.57M
Depreciation and amortization8.90M7.20M4.90M3.90M3.20M1.15M426.0K330.0K204.0K67.0K
EBITDA-222.8M-266.0M-254.8M-220.4M-164.0M-133.2M-75.7M-70.8M-19.6M-7.51M
Interest expense1.89M1.89M1.88M1.86M2.98M6.97M5.96M6.04M00
Income before tax-223.1M-258.7M-245.6M-221.9M-169.1M-139.7M-77.3M-74.5M-29.5M-42.9M
Income tax000-2.48M516.0K6.97M5.96M2.68M819.0K443.0K
Net income-223.1M-258.7M-245.6M-221.9M-169.1M-139.7M-77.3M-74.5M-19.6M-7.57M
Earnings per share, basic-2.01-2.73-2.92-3.26-2.67-2.52-1.58-1.89-2.88-1.11
Earnings per share, diluted-2.01-2.73-2.92-3.26-2.67-2.52-1.58-1.89-2.88-1.11

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents77.6M163.6M55.9M140.5M232.7M297.1M185.4M111.4M18.1M29.8M
Short-term investments111.4M208.7M317.3M215.9M156.0M185.6M118.7M94.4M096.7M
Inventory000
Current assets192.7M378.2M378.2M364.1M392.1M487.3M307.8M209.1M19.0M128.3M
Property, plant and equipment28.2M36.8M39.2M29.0M22.3M19.2M29.5M2.03M985.0K1.13M
Goodwill39.2M39.2M39.2M39.2M30.8M30.8M30.8M30.8M00
Total assets330.4M527.7M566.3M551.8M497.0M590.8M372.1M251.3M20.1M129.6M
Accounts payable1.63M1.77K36.7M48283534058901.59M
Current liabilities30.2M40.7M48.5M39.2M22.2M32.6M18.3M15.4M4.52M7.04M
Long-term debt35.1M45.0M41.4M49.5M49.0M
Total debt025.5M25.0M22.9M22.6M61.7M47.4M41.4M49.5M49.0M
Total liabilities53.2M64.5M73.8M62.1M42.3M87.3M64.8M57.3M4.63M56.5M
Shareholders' equity277.2M463.2M492.6M489.7M454.7M503.5M307.3M194.0M15.5M8.37M
Shares outstanding108.3M106.5M90.3M79.1M64.5M61.0M54.8M45.1M6.80M6.75M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-190.0M-209.7M-194.9M-178.1M-121.2M-74.6M-64.7M-53.8M-16.0M-5.50M
Capital spending-440.0K-5.86M-16.4M-8.36M-7.62M-20.6M-23.3M-1.45M-760.0K-335.0K
Free cash flow-190.5M-215.6M-211.4M-186.5M-128.8M-95.2M-87.9M-55.2M-16.7M-5.84M
Cash from investing103.8M131.7M-98.1M-69.3M18.9M-96.6M-39.0M-5.27M-760.0K-335.0K
Cash from financing148.0K185.7M208.4M155.3M37.7M283.0M177.8M153.5M25.4M16.0K
Dividends paid-172.0K-5.56M0-155.0K
Share buybacks-67.0K00-47.0K0-72.0K0000
Change in cash-86.1M107.7M-84.6M-92.2M-64.6M111.8M74.1M94.4M48.9M-50.2M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 20, 2026Insider tradeSEC
4 · Change in ownershipNov 20, 2026Insider tradeSEC
144 · Notice of proposed saleNov 18, 2026Other filingsSEC
144 · Notice of proposed saleNov 18, 2026Other filingsSEC
4 · Change in ownershipNov 17, 2026Insider tradeSEC
4 · Change in ownershipNov 17, 2026Insider tradeSEC
144 · Notice of proposed saleNov 13, 2026Other filingsSEC
144 · Notice of proposed saleNov 13, 2026Other filingsSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
8-K · Current reportNov 12, 2026ResultsSEC
Show 200 filings
FilingDateTypeFiled with
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
4 · Change in ownershipNov 9, 2026Insider tradeSEC
144 · Notice of proposed saleNov 9, 2026Other filingsSEC
144 · Notice of proposed saleNov 9, 2026Other filingsSEC
144 · Notice of proposed saleNov 5, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 30, 2026Big-stake noticeSEC
8-K · Current reportOct 6, 2026Material contractSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
144 · Notice of proposed saleSep 15, 2026Other filingsSEC
8-K · Current reportSep 15, 2026Current reportSEC
144 · Notice of proposed saleSep 14, 2026Other filingsSEC
144 · Notice of proposed saleSep 11, 2026Other filingsSEC
144 · Notice of proposed saleSep 11, 2026Other filingsSEC
25-NSESep 2, 2026Other filingsSEC
8-K · Current reportAug 27, 2026Management or board changeSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
144 · Notice of proposed saleAug 18, 2026Other filingsSEC
144 · Notice of proposed saleAug 18, 2026Other filingsSEC
144 · Notice of proposed saleAug 18, 2026Other filingsSEC
4 · Change in ownershipAug 17, 2026Insider tradeSEC
4 · Change in ownershipAug 17, 2026Insider tradeSEC
4 · Change in ownershipAug 13, 2026Insider tradeSEC
4 · Change in ownershipAug 13, 2026Insider tradeSEC
144 · Notice of proposed saleAug 13, 2026Other filingsSEC
144 · Notice of proposed saleAug 13, 2026Other filingsSEC
144 · Notice of proposed saleAug 11, 2026Other filingsSEC
144 · Notice of proposed saleAug 11, 2026Other filingsSEC
8-K · Current reportAug 10, 2026ResultsSEC
10-Q · Quarterly reportAug 10, 2026Quarterly reportSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
8-K · Current reportAug 3, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeJul 31, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansJul 14, 2026Offer documentSEC
3 · Initial statement of ownershipJul 8, 2026Insider tradeSEC
144 · Notice of proposed saleJul 7, 2026Other filingsSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
8-K · Current reportJun 30, 2026Management or board changeSEC
8-K · Current reportJun 12, 2026Acquisition or disposalSEC
SC TO-I/AMay 28, 2026Acquisition or disposalSEC
4 · Change in ownershipMay 28, 2026Insider tradeSEC
4 · Change in ownershipMay 26, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
144 · Notice of proposed saleMay 21, 2026Other filingsSEC
8-K · Current reportMay 21, 2026Meeting outcomeSEC
144 · Notice of proposed saleMay 19, 2026Other filingsSEC
144 · Notice of proposed saleMay 19, 2026Other filingsSEC
144 · Notice of proposed saleMay 19, 2026Other filingsSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
144 · Notice of proposed saleMay 13, 2026Other filingsSEC
144 · Notice of proposed saleMay 13, 2026Other filingsSEC
144 · Notice of proposed saleMay 13, 2026Other filingsSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
8-K · Current reportMay 7, 2026ResultsSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
144 · Notice of proposed saleMay 7, 2026Other filingsSEC
8-K · Current reportApr 28, 2026Material contractSEC
SC TO-IApr 27, 2026Acquisition or disposalSEC
ARS · Annual report to shareholdersApr 6, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 6, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 6, 2026Meeting noticeSEC
SC TO-CApr 3, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
8-K · Current reportMar 27, 2026Current reportSEC
PRE 14A · Preliminary proxy statementMar 24, 2026Meeting noticeSEC
EFFECT · Notice that a registration is effectiveMar 11, 2026Other filingsSEC
8-K · Current reportMar 10, 2026Material contractSEC
424B5 · ProspectusMar 10, 2026Offer documentSEC
CORRESP · Letter to the SECMar 6, 2026Other filingsSEC
UPLOAD · Letter from the SECMar 6, 2026Other filingsSEC
S-3 · Registration statementMar 2, 2026Offer documentSEC
8-K · Current reportFeb 26, 2026ResultsSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 13, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 13, 2026Other filingsSEC
144 · Notice of proposed saleFeb 13, 2026Other filingsSEC
144 · Notice of proposed saleFeb 13, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 30, 2026Big-stake noticeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipNov 20, 2025Insider tradeSEC
4 · Change in ownershipNov 20, 2025Insider tradeSEC
4 · Change in ownershipNov 20, 2025Insider tradeSEC
4 · Change in ownershipNov 20, 2025Insider tradeSEC
144 · Notice of proposed saleNov 18, 2025Other filingsSEC
144 · Notice of proposed saleNov 18, 2025Other filingsSEC
144 · Notice of proposed saleNov 18, 2025Other filingsSEC
144 · Notice of proposed saleNov 18, 2025Other filingsSEC
4 · Change in ownershipNov 10, 2025Insider tradeSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
4 · Change in ownershipOct 16, 2025Insider tradeSEC
144 · Notice of proposed saleOct 14, 2025Other filingsSEC
8-K · Current reportOct 14, 2025Current reportSEC
4 · Change in ownershipOct 8, 2025Insider tradeSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 3, 2025Insider tradeSEC
8-K · Current reportOct 3, 2025Management or board changeSEC
8-K · Current reportOct 3, 2025Current reportSEC
8-K · Current reportSep 29, 2025Management or board changeSEC
4 · Change in ownershipSep 23, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 22, 2025Insider tradeSEC
8-K · Current reportSep 17, 2025Material contractSEC
4 · Change in ownershipSep 9, 2025Insider tradeSEC
4 · Change in ownershipSep 9, 2025Insider tradeSEC
4 · Change in ownershipSep 9, 2025Insider tradeSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
8-K · Current reportAug 25, 2025Management or board changeSEC
4 · Change in ownershipAug 20, 2025Insider tradeSEC
4 · Change in ownershipAug 20, 2025Insider tradeSEC
4 · Change in ownershipAug 20, 2025Insider tradeSEC
4 · Change in ownershipAug 20, 2025Insider tradeSEC
8-K · Current reportAug 20, 2025Current reportSEC
144 · Notice of proposed saleAug 19, 2025Other filingsSEC
144 · Notice of proposed saleAug 19, 2025Other filingsSEC
144 · Notice of proposed saleAug 19, 2025Other filingsSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
144 · Notice of proposed saleAug 18, 2025Other filingsSEC
144 · Notice of proposed saleAug 18, 2025Other filingsSEC
144 · Notice of proposed saleAug 18, 2025Other filingsSEC
144 · Notice of proposed saleAug 14, 2025Other filingsSEC
144 · Notice of proposed saleAug 14, 2025Other filingsSEC
144 · Notice of proposed saleAug 14, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
4 · Change in ownershipAug 6, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 4, 2025Insider tradeSEC
8-K · Current reportJul 24, 2025Current reportSEC
8-K · Current reportJul 23, 2025Current reportSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
8-K · Current reportJul 17, 2025Current reportSEC
8-K · Current reportJul 11, 2025Management or board changeSEC
4 · Change in ownershipJul 8, 2025Insider tradeSEC
144 · Notice of proposed saleJul 3, 2025Other filingsSEC
8-K · Current reportJun 18, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 5, 2025Big-stake noticeSEC
8-K · Current reportMay 27, 2025Current reportSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 22, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
144 · Notice of proposed saleMay 20, 2025Other filingsSEC
144 · Notice of proposed saleMay 20, 2025Other filingsSEC
144 · Notice of proposed saleMay 20, 2025Other filingsSEC
144 · Notice of proposed saleMay 20, 2025Other filingsSEC
144 · Notice of proposed saleMay 20, 2025Other filingsSEC
144 · Notice of proposed saleMay 16, 2025Other filingsSEC
144 · Notice of proposed saleMay 16, 2025Other filingsSEC

This page holds 200 of 982 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Rocket Pharmaceuticals, Inc.’s releases · as of Oct 6, 2026

Common shares
109,774,597
Fully diluted
109,774,597

Fully diluted

LineShares
Common shares109,774,597

Warrants and options

Lot
Warrants · expiry not stated

Share count over time

CountShares
Nov 22, 2026109,774,597

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Rtw Investments, LP17.7M15.8%US$46.5MSep 30, 2026
BlackRock13.2M11.8%US$34.6MSep 30, 2026
Vanguard5.9M5.3%US$15.5MSep 30, 2026
Millennium4.82M4.3%US$12.7MSep 30, 2026
Citigroup Inc4.61M4.1%US$12.1MSep 30, 2026
Newtyn Management, LLC4M3.6%US$10.5MSep 30, 2026
Maverick Capital LTD3.84M3.4%US$10.1MSep 30, 2026
Marshall Wace, LLP3.51M3.1%US$9.24MSep 30, 2026
Monaco Asset Management SAM2.92M2.6%US$7.68MSep 30, 2026
Federated Hermes, Inc.2.53M2.3%US$6.65MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Rosalind Advisors, Inc.2.2M2.0%US$5.79MSep 30, 2026
State Street1.88M1.7%US$4.94MSep 30, 2026
Goldman Sachs1.83M1.6%US$4.81MSep 30, 2026
Geode Capital1.72M1.5%US$4.52MSep 30, 2026
AQR Capital Management LLC1.68M1.5%US$4.41MSep 30, 2026
Morgan Stanley1.5M1.3%US$3.94MSep 30, 2026
Dimensional1.35M1.2%US$3.54MSep 30, 2026
abrdn1.17M1.0%US$3.07MSep 30, 2026
Jacobs Levy Equity Management, Inc1.16M1.0%US$3.04MSep 30, 2026
Fidelity1.03M0.92%US$2.71MSep 30, 2026
Opaleye Management Inc.1M0.90%US$2.63MSep 30, 2026
Renaissance Technologies929K0.83%US$2.44MSep 30, 2026
D. E. Shaw & Co., Inc.806K0.72%US$2.12MSep 30, 2026
Schwab776K0.69%US$2.04MSep 30, 2026
JPMorgan763K0.68%US$1.98MSep 30, 2026
Bank of America744K0.67%US$1.96MSep 30, 2026
Northern Trust720K0.64%US$1.89MSep 30, 2026
Woodline Partners LP641K0.57%US$1.69MSep 30, 2026
Prosight Management, LP595K0.53%US$1.56MSep 30, 2026
Point72 Asset Management, L.P.517K0.46%US$1.36MSep 30, 2026
BNP Paribas450K0.40%US$1.18MSep 30, 2026
ADAR1 Capital Management, LLC443K0.40%US$1.16MSep 30, 2026
Susquehanna423K0.38%US$1.11MSep 30, 2026
Jump Financial, LLC421K0.38%US$1.11MSep 30, 2026
Citadel366K0.33%US$962KSep 30, 2026
Invesco338K0.30%US$889KSep 30, 2026
Man Group plc335K0.30%US$880KSep 30, 2026
LPL Financial LLC323K0.29%US$849KSep 30, 2026
Wellington319K0.29%US$840KSep 30, 2026
BNY257K0.23%US$675KSep 30, 2026
Two Sigma256K0.23%US$674KSep 30, 2026
Ameriprise247K0.22%US$650KSep 30, 2026
Privium Fund Management B.V.244K0.22%US$642KSep 30, 2026
UBS231K0.21%US$607KSep 30, 2026
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.224K0.20%US$589KSep 30, 2026
Hennion & Walsh Asset Management, Inc.220K0.20%US$580KSep 30, 2026
Nuveen211K0.19%US$555KSep 30, 2026
M28 Capital Management LP211K0.19%US$555KSep 30, 2026
Creative Planning207K0.19%US$545KSep 30, 2026
Squarepoint Ops LLC200K0.18%US$527KSep 30, 2026

This page holds 50 of 168 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund2.7M2.4%US$9.23MJun 30, 2026
iShares Russell 2000 ETF2.37M2.1%US$8.11MJun 30, 2026
Vanguard Strategic Equity Fund1.7M1.5%US$5.8MJun 30, 2026
Federated Hermes MDT Small Cap Core Fund1.04M0.93%US$3.23MJul 31, 2026
Vanguard Strategic Small-Cap Equity Fund1.01M0.90%US$3.44MJun 30, 2026
Vanguard Extended Market Index Fund1M0.90%US$3.42MJun 30, 2026
Fidelity Small Cap Index Fund985K0.88%US$3.06MJul 31, 2026
iShares Russell 2000 Value ETF845K0.76%US$2.89MJun 30, 2026
iShares Biotechnology ETF730K0.65%US$2.5MJun 30, 2026
Bridge Builder Small/Mid Cap Growth Fund729K0.65%US$2.49MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Vanguard Explorer Fund619K0.55%US$1.92MJul 31, 2026
Fidelity Extended Market Index Fund462K0.41%US$1.42MMay 31, 2026
Fidelity Enhanced Small Cap Core ETF460K0.41%US$1.57MJun 30, 2026
Vanguard Russell 2000 Index Fund435K0.39%US$1.34MMay 31, 2026
Federated Hermes MDT Small Cap Growth Fund433K0.39%US$1.35MJul 31, 2026
Schwab U.S. Small-Cap ETF426K0.38%US$1.31MMay 31, 2026
Vanguard Market Neutral Fund387K0.35%US$1.32MJun 30, 2026
AQR Small Cap Multi-Style Fund367K0.33%US$1.26MJun 30, 2026
Small Company Growth Portfolio338K0.30%US$1.16MJun 30, 2026
Invesco RAFI US 1500 Small-Mid ETF330K0.30%US$1.03MJul 31, 2026
iShares Micro-Cap ETF304K0.27%US$1.04MJun 30, 2026
Multi-Manager Small Cap Equity Strategies Fund267K0.24%US$821KMay 31, 2026
Dimensional U.S. Small Cap ETF253K0.23%US$787KJul 31, 2026
U.S. Micro Cap Portfolio248K0.22%US$771KJul 31, 2026
Vanguard Health Care Index Fund242K0.22%US$744KMay 31, 2026
U.S. Small Cap Portfolio232K0.21%US$721KJul 31, 2026
Schwab Small-Cap Index Fund220K0.20%US$685KJul 31, 2026
Goldman Sachs Small Cap Value Insights Fund218K0.20%US$679KJul 31, 2026
Goldman Sachs Small Cap Equity Insights Fund182K0.16%US$566KJul 31, 2026
Master Small Cap Index Series169K0.15%US$578KJun 30, 2026
NVIT Multi-Manager Small Company Fund162K0.15%US$554KJun 30, 2026
Fidelity Total Market Index Fund161K0.14%US$495KMay 31, 2026
NVIT Small Cap Value Fund157K0.14%US$536KJun 30, 2026
Fidelity Series Total Market Index Fund133K0.12%US$407KMay 31, 2026
Small Cap Equity Fund132K0.12%US$452KJun 30, 2026
Fidelity Small Cap Value Index Fund126K0.11%US$432KJun 30, 2026
Nuveen Small Cap Blend Index Fund121K0.11%US$377KJul 31, 2026
EQ/Small Company Index Portfolio120K0.11%US$411KJun 30, 2026
iShares Core S&P Total U.S. Stock Market ETF119K0.11%US$407KJun 30, 2026
Virtus Biotech Clinical Trials Etf113K0.10%US$352KJul 31, 2026
EQ/2000 Managed Volatility Portfolio92,3670.08%US$316KJun 30, 2026
Avantis U.S. Small Cap Equity ETF90,9050.08%US$279KMay 31, 2026
JPMorgan Small Cap Value Fund89,5210.08%US$306KJun 30, 2026
Dimensional U.S. Core Equity 2 ETF81,2260.07%US$253KJul 31, 2026
Fidelity Nasdaq Composite Index Fund80,2350.07%US$246KMay 31, 2026
BlackRock Advantage SMID Cap Fund, Inc.79,9920.07%US$274KJun 30, 2026
JPMorgan U.S. Small Company Fund70,9980.06%US$243KJun 30, 2026
Goldman Sachs Variable Insurance Trust Small Cap Equity Insights Fund68,9880.06%US$236KJun 30, 2026
NVIT GS Small Cap Equity Insights Fund68,5580.06%US$234KJun 30, 2026
EQ/AB Small Cap Growth Portfolio60,2600.05%US$206KJun 30, 2026

This page holds 50 of 160 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Wilson Martin
Officer: General Counsel
Sale677USD 2.18US$1,475Nov 18, 2026
Shah Gaurav
Officer: CEO
Sale2,216USD 2.18US$4,826Nov 18, 2026
Wilson Martin
Officer: General Counsel
Sale4,087USD 2.25US$9,196Nov 13, 2026
Shah Gaurav
Officer: CEO
Sale3,020USD 2.25US$6,795Nov 13, 2026
Chaudhuri Sarbani
Officer: See Remarks
Sale4,872USD 2.33US$11,337Nov 9, 2026
Wilson Martin
Officer: General Counsel
Sale53,389USD 2.39US$128KNov 5, 2026
Wilson Martin
Officer: General Counsel
Sale75,364USD 3.40US$256KSep 11, 2026
Shah Gaurav
Officer: CEO
Sale2,293USD 3.38US$7,750Aug 18, 2026
Wilson Martin
Officer: General Counsel
Sale631USD 3.38US$2,133Aug 18, 2026
Wilson Martin
Officer: General Counsel
Sale3,493USD 3.38US$11,806Aug 13, 2026
All 21 trades
TradeTradeSharesPriceValueDate
Shah Gaurav
Officer: CEO
Sale2,837USD 3.38US$9,589Aug 13, 2026
Chaudhuri Sarbani
Officer: See Remarks
Sale4,701USD 3.50US$16,454Aug 11, 2026
Stevens Christopher James
Officer: Chief Operating Officer
Sale36,658USD 3.50US$128KAug 11, 2026
Shah Gaurav
Officer: CEO
Sale55,684USD 3.09US$172KMay 21, 2026
Militello John
Officer: See Remarks
Sale384USD 3.01US$1,156May 19, 2026
Wilson Martin
Officer: General Counsel
Sale662USD 3.01US$1,993May 19, 2026
Shah Gaurav
Officer: CEO
Sale2,409USD 3.01US$7,251May 19, 2026
Militello John
Officer: See Remarks
Sale855USD 3.61US$3,087May 13, 2026
Shah Gaurav
Officer: CEO
Sale2,728USD 3.61US$9,848May 13, 2026
Wilson Martin
Officer: General Counsel
Sale3,361USD 3.61US$12,133May 13, 2026
Chaudhuri Sarbani
Officer: See Remarks
Sale17,650USD 3.84US$67,776May 7, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Patrick Machado
Other companies: Alumis Inc. (Independent Board Member · Since at least Jun 27, 2024); Xenon Pharmaceuticals Inc. (Director · Since at least Nov 5, 2020); Arcus Biosciences, Inc. (Board Member · Since at least Dec 10, 2019); Adverum Biotechnologies Inc (Director · Since at least Mar 14, 2017); Turnstone Biologics Corp. (Director · Jul 20, 2023 – Jul 20, 2023 · Past); Acelyrin, Inc. (Director · May 4, 2023 – May 21, 2025 · Past); Roivant Sciences Ltd. (Director · Oct 1, 2021 – Oct 1, 2021 · Past); Principia Biopharma Inc (Director · Jun 11, 2019 – Sep 28, 2020 · Past); Turning Point Therapeutics Inc (Director · May 13, 2019 – Aug 17, 2022 · Past); Endocyte Inc (Director · Feb 27, 2018 – Dec 21, 2018 · Past); Sio Gene Therapies Inc (Director · Jul 17, 2017 – Jul 17, 2017 · Past); Scynexis, Inc. (Director · Sep 24, 2015 – Jan 2, 2019 · Past); Chimerix Inc (Director · Jun 20, 2014 – Jun 9, 2023 · Past); Medivation Inc (Director · Jun 5, 2007 – Sep 28, 2016 · Past)
Director · Aug 17, 2016 – Jun 20, 2017 · Past
Pedro P Granadillo
Other companies: Orchestra BioMed Holdings, Inc. (Director · Aug 3, 2020 – Aug 3, 2020 · Past); Immunovant, Inc. (Director · May 9, 2019 – May 9, 2019 · Past); NPS Pharmaceuticals Inc (Director · Nov 17, 2010 – Feb 21, 2015 · Past); Dendreon Corp (Director · Oct 7, 2009 – Jan 3, 2014 · Past); Capricor Therapeutics, Inc. (Director · Oct 16, 2007 – May 10, 2011 · Past); Haemonetics Corporation (Director · May 5, 2006 – Nov 8, 2018 · Past); First Indiana Corp (Director · Jan 3, 2006 – Jan 2, 2008 · Past)
Director · Since at least Jan 4, 2018
Timothy J Barberich
Other companies: TScan Therapeutics, Inc. (Director · Jul 15, 2021 – Dec 18, 2023 · Past); Korro Bio, Inc. (Director · Oct 2, 2019 – Aug 17, 2022 · Past); Eledon Pharmaceuticals, Inc. (Director · Sep 16, 2014 – Jun 15, 2016 · Past); Verastem, Inc. (Director · Mar 10, 2014 – Jun 28, 2021 · Past); HeartWare International Inc (Director · Apr 29, 2008 – Aug 23, 2016 · Past); Biosphere Medical Inc (Director · May 10, 2006 – Sep 10, 2010 · Past); Sepracor Inc (Director · Mar 16, 2006 – Oct 20, 2009 · Past)
Director · Sep 28, 2016 – Jun 20, 2017 · Past
Argeris N Karabelas
Other companies: Regenxbio Inc. (Director · Since at least Sep 16, 2015); Bausch Health Companies Inc. (Director · Jun 14, 2016 – Jun 24, 2022 · Past); Human Genome Sciences Inc (Director · Apr 27, 2006 – Jul 30, 2012 · Past); Vanda Pharmaceuticals Inc. (Director · Apr 12, 2006 – Jun 16, 2011 · Past); Nitromed Inc (Director · Mar 20, 2006 – Apr 24, 2009 · Past)
Director · Feb 17, 2015 – Jun 24, 2015 · Past
Carsten Boess
Other companies: Atrium Therapeutics, Inc. (Director · Since at least Nov 10, 2025); Avidity Biosciences, Inc (Director · Since at least Jun 11, 2020); Orchestra BioMed Holdings, Inc. (Director · Aug 3, 2020 – Aug 3, 2020 · Past); Synageva BioPharma Corp (SVP, Chief Financial Officer · Nov 2, 2011 – Jun 22, 2015 · Past); Insulet Corporation (Vice President, International · May 14, 2007 – Apr 25, 2011 · Past)
Director · Since at least Jan 11, 2016
Keith Woods
Other companies: Neurogene Inc. (Director · Since at least Jun 12, 2025); Scholar Rock Holding Corporation (Chief Operating Officer · Since at least Apr 27, 2025); TScan Therapeutics, Inc. (Director · Since at least Dec 6, 2023); X4 Pharmaceuticals, Inc. (Director · Since at least Oct 16, 2023)
Director · Dec 7, 2023 – Jun 13, 2024 · Past
Mikael Dolsten
Other companies: Apellis Pharmaceuticals, Inc. (Director · Since at least Feb 27, 2026); Agilent Technologies, Inc. (Director · Since at least Sep 21, 2021); Karyopharm Therapeutics Inc. (Director · Mar 31, 2015 – May 21, 2021 · Past); Pfizer, Inc. (President R&D · Oct 16, 2009 – Sep 12, 2024 · Past)
Director · Since at least Sep 5, 2024
Gary Phillips
Other companies: Aldeyra Therapeutics, Inc. (Director · Since at least May 1, 2014); Egalet Corporation (Director · Jun 18, 2019 – May 20, 2020 · Past); Mallinckrodt Inc (Exec. VP & Chief Strategy Ofcr · Oct 21, 2013 – Jan 3, 2018 · Past)
Director · Oct 13, 2015 – Jun 20, 2017 · Past
Martin Vogelbaum
Other companies: NephroGenex Inc (Director · Feb 10, 2014 – May 15, 2014 · Past); Tvardi Therapeutics, Inc. (Director · Jan 30, 2014 – Jun 4, 2024 · Past); MiddleBrook Pharmaceuticals Inc (Director · Apr 20, 2007 – Jun 23, 2009 · Past)
Director · Feb 17, 2015 – Jun 24, 2015 · Past
Kamran Alam
Other companies: Taysha Gene Therapies, Inc. (Chief Financial Officer · Since at least Sep 23, 2020); Neurogene Inc. (CFO, Vice President Finance · Mar 9, 2018 – Aug 7, 2018 · Past)
SVP - Finance & PFO · Oct 28, 2019 – Feb 6, 2020 · Past
All 35 people
PersonSeat
Naveen Yalamanchi
Other companies: Orchestra BioMed Holdings, Inc. (Chief Financial Officer, Director · Aug 3, 2020 – Aug 3, 2020 · Past); Immunovant, Inc. (Vice President and CFO, Director · May 9, 2019 – May 9, 2019 · Past)
Director · Jan 4, 2018 – Jun 13, 2024 · Past
Syed Ali-aamir Rizvi
Other companies: Poseida Therapeutics Inc (Chief Medical Officer · Apr 1, 2024 – Jan 8, 2025 · Past); Caribou Biosciences, Inc. (Chief Medical Officer · Jan 18, 2022 – Feb 21, 2023 · Past)
Chief Medical Officer · Since at least Sep 15, 2025
David P. Southwell
Other companies: PTC Therapeutics, Inc. (Director · Since at least Sep 9, 2025)
Director · Since at least Jun 18, 2025
Elisabeth Björk
Other companies: Pharvaris N.V. (Director · Since at least Mar 18, 2026)
Director · Since at least Apr 20, 2020
Fady I. Malik
Other companies: Cytokinetics, Incorporated (EVP, Research & Development · Since at least Jun 1, 2012)
Independent Director · Since at least Mar 10, 2022
Gaurav Shah
Other companies: Tourmaline Bio Inc. (Director · May 6, 2021 – Jun 13, 2023 · Past)
Chief Executive Officer · Since at least Jan 4, 2018
Gotham Makker
Other companies: Immunovant, Inc. (Director · May 9, 2019 – May 9, 2019 · Past)
Director · Since at least Jan 4, 2018
Jonathan David Schwartz
Other companies: Tabula Rasa HealthCare Inc (Director · Sep 13, 2022 – Nov 3, 2023 · Past)
See Remarks · Since at least Mar 30, 2022
Roderick Wong
Other companies: Allurion Technologies, Inc. (Director · Since at least Apr 16, 2025)
Director · Since at least Jun 13, 2024
Aaron OndreyChief Financial Officer · Since at least Mar 25, 2024
Brian BatchelderSee Remarks · Jan 4, 2018 – Jan 4, 2018 · Past
Carlos Garcia-ParadaChief Financial Officer · Jan 4, 2021 – Feb 14, 2022 · Past
Carlos MartinChief Commercial Officer · Nov 13, 2025 – Nov 5, 2026 · Past
Christopher James StevensChief Operating Officer · Since at least Jul 7, 2025
Dale RitterVice President, Finance · Mar 22, 2016 – Sep 14, 2017 · Past
Devang KantesariaDirector · Feb 17, 2015 – Feb 17, 2015 · Past
John MilitelloSee Remarks · Since at least Feb 17, 2023
Joseph ManhedePrincipal Accounting Officer · Since at least Jul 8, 2026
Kinnari PatelSee Remarks · Jan 4, 2018 – May 20, 2025 · Past
Mark Andrew WhiteSee Remarks · Apr 4, 2023 – Oct 31, 2024 · Past
Martin WilsonGeneral Counsel · Since at least May 16, 2025
Paul G HowesDirector · Feb 17, 2015 – Jun 20, 2017 · Past
Peter FongChairman of the Board · Since at least Sep 24, 2025
Piratip PratumsuwanDirector · Since at least Jan 27, 2025
Sarbani ChaudhuriSee Remarks · Since at least Apr 7, 2025

Open People

Log in to ask 6ix AI your own questions about Rocket Pharmaceuticals, Inc.